Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05024929 · ClinicalTrials.gov registry record
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
A clinical trial of Pediatric Cancer and Papillary Thyroid Cancer, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- 32
- Enrollment target
- 9
- Study locations
NCT05024929: Recruiting study of Pediatric Cancer and Papillary Thyroid Cancer, sponsored by Children's Hospital of Philadelphia.
NCT05024929 is a study of Pediatric Cancer and Papillary Thyroid Cancer that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 32 participants, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05024929, a study of Pediatric Cancer and Papillary Thyroid Cancer, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- 32 participants
- Enrollment target
- 9
- Study locations
Study Summary
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.
Primary Outcome
The primary outcome measure is to determine the proportion of patients with differentiated thyroid cancer metastatic to the lungs for whom oncogene-specific, targeted therapy increases tumor RAI-avidity.
Conditions Studied
Interventions
- PROCEDURE Whole body scan
Study Locations (9)
Texas
- MD Anderson Cancer Center - Houston
- Texas Children's Hospital - Houston
California
- University of California San Francisco - San Francisco
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Washington
- Seattle Children's Hospital - Seattle
New South Wales
- Children's Hospital Westmead - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2033-02-01 |
What NCT05024929 shows while recruiting
NCT05024929 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Whole body scan is the first listed.
NCT05024929 lists 9 locations in 8 states (Texas, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT05024929 about?
NCT05024929 is a clinical study titled "Targeted Therapy to Increase RAI Uptake in Metastatic DTC". Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drug...
What is the current status of trial NCT05024929?
This trial is currently recruiting. The enrollment target is 32 participants. The study started on 2021-07-16. Estimated completion is 2033-02-01.
What conditions does trial NCT05024929 study?
This clinical trial studies the following conditions: Pediatric Cancer, Papillary Thyroid Cancer, Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT05024929?
The interventions under investigation include: Whole body scan (PROCEDURE).
Who is sponsoring clinical trial NCT05024929?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05024929 being conducted?
This trial has 9 study locations across California, Georgia, Massachusetts, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05024929's enrollment target sits among peer trials
32 40th of 51 higher than 12 of 51 other Pediatric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
-
Ovarian Tissue Cryopreservation in Post Pubertal (OTC-Post Pubertal)
RECRUITING
-
Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer
RECRUITING · NA
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI